EZH2 and Burkitt lymphoma: In this study, MS1943, a PROTAC-based EZH2 degrader, demonstrated notable efficacy in suppressing human lymphoma cell lines, especially Burkitt’s lymphoma, compared to the conventional EZH2 inhibitor, Tazemetostat (Figure 1A).